IGF1 and glioblastoma: Currently, the treatments that prolong to some extent the survival of GBM patients are invasive surgery, and aggressive radiotherapy, followed by chemotherapy (temolozomid [3,4]); treatment with antibodies and inhibitors (imatinib, getifinib, avastin [5]), or anti-growth factor therapy (for instance antisense strategies against IGF-I or TGFβ [6,7]), which increase survival up to 18-24 months, instead of 8-11 months of classic survival if only surgery and radiotherapy are applied.